Clinical Trials Directory

Trials / Unknown

UnknownNCT04770350

Open Label Study for the Use of Transcranial Ultrasound for Treatment of Age-Related Frailty

Status
Unknown
Phase
EARLY_Phase 1
Study type
Interventional
Enrollment
50 (estimated)
Sponsor
Neurological Associates of West Los Angeles · Academic / Other
Sex
All
Age
45 Years – 95 Years
Healthy volunteers
Not accepted

Summary

The purpose of this Phase I open label study is to evaluate longer term tolerability and potential effectiveness of transcranial ultrasound in people with age-related frailty.

Detailed description

This study is designed to evaluate the safety and efficacy of focused ultrasound in patients with age-related frailty characterized by reduced physical and immunological functioning. The safety of this protocol will be closely monitored and data will be used to determine whether any significant safety issues exist when using focused ultrasound. Adverse events will be noted whenever they occur but will be recorded at the time of the procedure and throughout routine follow-ups, which will persist weekly throughout the duration of the active study protocol. Patients deemed potentially appropriate candidates for focused ultrasound therapy will be treated with 8 sessions of transcranial ultrasound, each of which consists of 10 to 30 minutes of active administration. Clinical and safety outcome measures will be obtained throughout and after completion of the study protocol.

Conditions

Interventions

TypeNameDescription
DEVICEFocused UltrasoundThe DWL Doppler ultrasound device enables visual and auditory waveform confirmation of the middle cerebral artery, and optical tracking technology (e.g., AntNeuro Visor2™ system) may be used in tandem with the Brainsonix ultrasound device to track a patient's brain in virtual space as well as their physical location, thereby ensuring accurate placement.

Timeline

Start date
2023-09-01
Primary completion
2024-09-30
Completion
2024-12-31
First posted
2021-02-25
Last updated
2022-09-28

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT04770350. Inclusion in this directory is not an endorsement.